Mouse Anti Human Glutathione S-transferase Mu1 Hybridoma [DQUD-HTUNv2-7]

Glutathione S-Transferases (GSTs)(1) are enzymes catalyzing reactive oxygen species which are believed to participate in the carcinogenesis of different cancers. We aimed to assess the distribution and the potential impact of GSTT1 and GSTM1 polymorphisms on the risk of several types of cancers in an Iranian population. In this case-control study, 213 cancer patients along with 213 healthy volunteers were included. GSTM1 and GSTT1 polymorphisms were genotyped using multiplex-PCR. In all the subjects, GSTT1 (+)/GSTM1 (-) genotype (43.9%) was of the highest frequency following by GSTT1 (+)/GSTM1 (+) (35.9%). No significant differences were observed in the distributions of GSTM1 and GSTT1 gene polymorphisms between cases (45.5% and 9.4%, respectively) and controls (42.3% and 9.9% respectively). The GSTM1 gene polymorphism was not associated with the overall risk of cancer (OR = 0.85), nor with the individual risk of breast (OR = 1.04), thyroid (0.63), lymphatic (1.05) or bone (0.97) neoplasms. Accordingly, there were no significant associations between GSTT1 polymorphism with neither overall cancer risk (1), nor with the risk of breast (OR = 1.36), thyroid (0.93), lymphatic (0.84) and bone (1.64) tumors. Although statistically insignificant, GSTT1(-)/GSTM1(-) genotype represented the highest risk for lymphoma (OR = 1.89, 95% CI: 0.75-4.81, P = 0.13). Our results indicated no significant association between GSTM1 and GSTT1 polymorphisms and risk of cancers in southeast population of Iran.

Aim of Study: To further evaluate the influence of glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes on bladder cancer risk, we conducted a meta-analysis in the Chinese population. Materials and Methods: PubMed and Chinese databases were electronically searched through April 2016. Results: Nine studies were included for our meta-analysis, involving 1646 bladder cancer cases and 1938 controls. In general, our findings indicated that a significant association existed between GSTM1-null genotype and the risk of bladder cancer in the studied Chinese population (odds ratio = 1.56, 95% confidence interval: 1.36u1.79). However, no significant association between GSTT1 polymorphism and bladder cancer was found. After stratification of the subgroup analyses by source of controls and geographical areas, a substantially elevated risk was revealed between GSTM1-null genotype and bladder cancer in the population-based studies and those conducted in South China and North China. Conclusion: Our meta-analysis suggested that GSTM1-null genotype is associated with an increased bladder cancer risk in the Chinese individuals.